Aaron C. Logan

6.7k total citations
117 papers, 2.6k citations indexed

About

Aaron C. Logan is a scholar working on Hematology, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Aaron C. Logan has authored 117 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Hematology, 41 papers in Oncology and 38 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Aaron C. Logan's work include Acute Lymphoblastic Leukemia research (35 papers), CAR-T cell therapy research (29 papers) and Chronic Myeloid Leukemia Treatments (23 papers). Aaron C. Logan is often cited by papers focused on Acute Lymphoblastic Leukemia research (35 papers), CAR-T cell therapy research (29 papers) and Chronic Myeloid Leukemia Treatments (23 papers). Aaron C. Logan collaborates with scholars based in United States, United Kingdom and Germany. Aaron C. Logan's co-authors include David B. Miklos, Donald B. Kohn, Chloe C. Y. Wong, Randall S. Stafford, Veronica Yank, R. M. Marquis, Malek Faham, Carolyn Lutzko, Victoria Carlton and Lori Styles and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Aaron C. Logan

112 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Aaron C. Logan United States	29	1.1k	567	531	522	491	117	2.6k
Hyoung Jin Kang South Korea	27	973 0.9×	600 1.1×	673 1.3×	394 0.8×	542 1.1×	248	2.9k
Irene Lorand‐Metze Brazil	27	1.2k 1.0×	671 1.2×	438 0.8×	488 0.9×	291 0.6×	205	2.5k
Ron Ram Israel	26	1.1k 1.0×	355 0.6×	695 1.3×	338 0.6×	509 1.0×	139	2.3k
Arnaud Petit France	25	969 0.9×	508 0.9×	305 0.6×	288 0.6×	630 1.3×	129	2.3k
Arcangelo Prete Italy	32	1.2k 1.1×	575 1.0×	826 1.6×	369 0.7×	479 1.0×	132	3.0k
Prasad Mathew United States	28	1.3k 1.2×	587 1.0×	501 0.9×	212 0.4×	325 0.7×	90	3.0k
Armin Gerbitz Canada	23	1.4k 1.2×	468 0.8×	646 1.2×	1.1k 2.1×	251 0.5×	107	2.6k
Giuseppe Milone Italy	31	2.2k 1.9×	1.2k 2.0×	851 1.6×	466 0.9×	553 1.1×	142	3.2k
John J. Cush United States	31	1.2k 1.0×	529 0.9×	461 0.9×	1.6k 3.0×	309 0.6×	59	4.3k
Belinda Pinto Simões Brazil	27	557 0.5×	484 0.9×	519 1.0×	479 0.9×	274 0.6×	137	2.8k

Countries citing papers authored by Aaron C. Logan

Since Specialization

Citations

This map shows the geographic impact of Aaron C. Logan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aaron C. Logan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aaron C. Logan more than expected).

Fields of papers citing papers by Aaron C. Logan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aaron C. Logan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aaron C. Logan. The network helps show where Aaron C. Logan may publish in the future.

Co-authorship network of co-authors of Aaron C. Logan

This figure shows the co-authorship network connecting the top 25 collaborators of Aaron C. Logan. A scholar is included among the top collaborators of Aaron C. Logan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aaron C. Logan. Aaron C. Logan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Park, Jae H., Paul Shaughnessy, Aaron C. Logan, et al.. (2025). Deep Molecular Remission Predicts Better Clinical Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) Treated with Obecabtagene Autoleucel (obe-cel). Transplantation and Cellular Therapy. 31(2). S216–S217. 1 indexed citations

Popescu, Bogdan, Matthew F. Jones, Cheryl A.C. Peretz, et al.. (2025). Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML. Blood. 147(3). 276–289. 1 indexed citations

Jonas, Brian A., Peter Curtin, Gary J. Schiller, et al.. (2025). A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503). Leukemia Research. 155. 107717–107717.

Shah, Bijal, Jeremy Pantin, Karamjeet Sandhu, et al.. (2024). Healthcare Resource Utilization and Costs Associated with Managing CRS and ICANS in Patients with Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia Receiving Obecabtagene autoleucel (obe-cel). Blood. 144(Supplement 1). 4837–4837.

Oluwole, Olalekan O., Armin Ghobadi, Ryan D. Cassaday, et al.. (2024). Long-term survival outcomes of patients (pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3.. Journal of Clinical Oncology. 42(16_suppl). 6531–6531. 3 indexed citations

Oliai, Caspian, Sunmin Park, Brian A. Jonas, et al.. (2024). CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial. Leukemia & lymphoma. 66(4). 773–779.

Park, Jae H., Paul Shaughnessy, Aaron C. Logan, et al.. (2024). Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes. Blood. 144(Supplement 1). 963–963. 1 indexed citations

Logan, Aaron C.. (2023). Adult Acute Lymphocytic Leukemia: Strategies for Selection of Consolidation Therapy. Journal of the National Comprehensive Cancer Network. 21(Supplement). 9–12. 1 indexed citations

Huang, Li‐Wen, Ying Shi, Charalambos Andreadis, et al.. (2023). Association of geriatric measures and global frailty with cognitive decline after allogeneic hematopoietic cell transplantation in older adults. Journal of Geriatric Oncology. 14(8). 101623–101623. 5 indexed citations

10.

Huang, Li‐Wen, Ying Sheng, Charalambos Andreadis, et al.. (2022). Patterns and Predictors of Functional Decline after Allogeneic Hematopoietic Cell Transplantation in Older Adults. Transplantation and Cellular Therapy. 28(6). 309.e1–309.e9. 3 indexed citations

11.

Banerjee, Rahul, Amar H. Kelkar, Aaron C. Logan, Navneet S. Majhail, & Naveen Pemmaraju. (2021). The Democratization of Scientific Conferences: Twitter in the Era of COVID-19 and Beyond. Current Hematologic Malignancy Reports. 16(2). 132–139. 9 indexed citations

12.

Sheng, Ying, Chiung‐Yu Huang, Charalambos Andreadis, et al.. (2020). Serial comprehensive geriatric and quality of life assessments in adults age ≥ 50 years undergoing autologous hematopoietic cell transplantation. Journal of Geriatric Oncology. 12(4). 531–539. 4 indexed citations

13.

Pang, Wendy W., Agnieszka Czechowicz, Aaron C. Logan, et al.. (2019). Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice. Blood. 133(19). 2069–2078. 43 indexed citations

14.

Waller, Edmund K., David B. Miklos, Corey Cutler, et al.. (2019). Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study. Biology of Blood and Marrow Transplantation. 25(10). 2002–2007. 66 indexed citations

15.

Wieduwilt, Matthew J., Brian A. Jonas, Gary J. Schiller, et al.. (2018). A Phase II Study of Pegylated Asparaginase, Cyclophosphamide, Rituximab, and Dasatinib Added to the UCSF 8707 (Linker 4-drug) Regimen with Liposomal Cytarabine CNS Prophylaxis for Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): University of California Hematologic Malignancies Consortium Study (UCHMC) 1401. Blood. 132(Supplement 1). 4018–4018. 5 indexed citations

16.

Logan, Aaron C., et al.. (2017). The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplantation: Why the quest for meaningful prophylaxis still matters. Blood Reviews. 31(3). 173–183. 55 indexed citations

17.

Saba, Julie D. & Aaron C. Logan. (2017). Obinutuzumab‐induced serum sickness following salvage therapy for chronic lymphocytic leukemia. Clinical Case Reports. 5(6). 891–893. 1 indexed citations

18.

Miklos, David B., Corey Cutler, Mukta Arora, et al.. (2016). Multicenter Open-Label Phase 2 Study of Ibrutinib in Chronic Graft Versus Host Disease (cGVHD) after Failure of Corticosteroids. Blood. 128(22). LBA–3. 14 indexed citations

19.

Mannis, Gabriel N., Thomas G. Martin, Lloyd E. Damon, et al.. (2015). Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission. Leukemia & lymphoma. 57(7). 1560–1566. 8 indexed citations

20.

Logan, Aaron C.. (1986). The beginnings of thoracic surgery.. PubMed. 24(4). 136–8. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact